Immune response modifiers: Imiquimod and future drugs for modulating the immune response

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 343-352

  Tomai, Mark A ^a   Miller, Richard L ^a   Lipson, Kenneth E ^a   Vasilakos, John P ^a   Woulfe, Susan L ^a  

^a 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

002; 2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; 8 OXOGUANOSINE DERIVATIVE; 851; 852A; 854; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA INTERFERON; ANA 975; AVE 0675; CPG 10101; CPG 2006; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; ISATORIBINE; PF 3512676; PROMUNE; R 1354; R 850; RECEPTOR STIMULATING AGENT; RESIQUIMOD; SM 360320; SOTIRIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VAXIMMUNE;

ACTINIC KERATOSIS; ATOPY; BASAL CELL CARCINOMA; CANCER; CLINICAL TRIAL; CONDYLOMA; DRUG APPROVAL; DRUG INDICATION; DRUG STRUCTURE; HUMAN; IMMUNOMODULATION; INFECTION; INNATE IMMUNITY; NONHUMAN; REVIEW;

EID: 33751162833     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.08.003     Document Type: Review

References (39)

1. O'Neill L.A.J. Immunity's early-warning system. Sci. Am. 292 (2005) 24-31
2. Janeway C.A., and Medzhitov R. Innate immune recognition. Ann. Rev. Immunol. 20 (2002) 197-216
3. Akira S., et al. Pathogen recognition and innate immunity. Cell 124 (2005) 783-801
4. Miller R.L., et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 21 (1999) 1-14
5. Gibson S.J., et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 218 (2002) 74-86
6. Stanley M.A. Imiquimod and the imidazoquinolines: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27 (2002) 571-577
7. Palamara F., et al. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. 173 (2004) 3051-3061
8. Chang Y.C., et al. Current and potential future uses of imiquimod. South. Med. J. 98 (2005) 914-920
9. Hemmi H., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent pathway. Nat. Immunol. 3 (2002) 196-200
10. Williford P., et al. R-850: A new immune response modifier for the treatment of actinic keratosis: results of two phase II studies. J. Am. Acad. Dermatol. 54 (2006) 73
11. Dudek A., et al. Immune response activation by a toll-like receptor 7 agonist: results of a phase 1 study. J. Clin. Oncol. 23 Suppl. 16S (2005) 2515
12. Horsmans Y., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentrations in chronic hepatitis C infections. Hepatology 42 (2005) 724-731
13. Lee J., et al. Activation of anti-hepatitis C virus responses via toll-like receptor 7. Proc. Nat. Acad. Sci. U S A 103 (2006) 1828-1833
14. Gorden K.B., et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174 (2005) 1259-1268
15. Tomai M.A., et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res. 28 (1995) 253-264
16. Wu J.J., et al. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res. 64 (2004) 79-83
17. Vasilakos J.P., et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 204 (2000) 64-74
18. Nair S., et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171 (2003) 6275-6282
19. Wille-Reece U., et al. Immunization with HIV-1 gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 gag-specific Th1 and CD8+ T cell responses. J. Immunol. 174 (2005) 7676-7683
20. Weertna R.D., et al. TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine 23 (2005) 5263-5270
21. Wagner T.L., et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers R-848 and imiquimod. Cell. Immunol. 191 (1999) 10-19
22. Quarcoo D., et al. Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. J. Clin. Exp. Allergy 34 (2004) 1314-1320
23. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
24. Amlie-Lefond C., et al. Innate immunity for biodefense: a strategy whose time has come. J. Allergy Clin. Immunol. 116 (2005) 1134-1142
25. Gorski K.S., et al. Distinct indirect pathways govern human NK-cell activation by TLR7 and TLR8 agonists. Int. Immunol. 18 (2006) 1115-1126
26. Velasco G., et al. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am. J. Respir. Cell. Mol. Biol. 32 (2005) 218-224
27. Cluff C.W., et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. 73 (2005) 3044-3052
28. Cook D.N., et al. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 5 (2004) 975-979
29. Uematsu S., et al. Therapeutic targeting of toll-like receptors. Drug Discov. Today 1 (2004) 299-304
30. Rossignol D.P., and Lynn M. TLR4 antagonists for endotoxemia and beyond. Curr. Opin. Invest. Drugs 6 (2005) 496-502
31. Fort M.A., et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J. Immunol. 174 (2005) 6416-6423
32. Krieg A.M., et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U S A 95 (1998) 12631-12636
33. Gursel I., et al. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J. Immunol. 171 (2003) 1393-1400
34. Schender J., et al. Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J. Virol. 79 (2005) 5507-5515
35. Barrat F.J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202 (2005) 1131-1139
36. Rutz M., et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 34 (2004) 2541-2550
37. Ii M., et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluoropheny)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 69 (2006) 1288-1295
38. Bartfai T., et al. A low molecular weight mimic of the toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. U S A 100 (2003) 7971-7976
39. Wess L., et al. The toll collectors. Biocentury 13 (2005) A1-A23